You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
新股速遞 | 泰格醫藥H股一手入場費10,100.77港元,外資"買爆"A股
uSMART友信智投 07-28 14:30

uSMART友信智投7月28日消息,淡馬錫、高瓴加持的泰格醫藥(3347.HK)今起招股,將成為繼藥明康得、康龍化成之後的第三家A+HCRO企業

【招股簡況】

招股價區間:88-100港元/H股

每手股數:100

一手入場費:10,100.77港元

保薦人:美林遠東、海通國際、中信里昂、中金公司

穩定價格操作人:美林遠東

招股日期:7月28日-31日

公佈中簽日:8月6日

預期上市日:8月7日

下圖為可申購檔位:

圖片來源:泰格醫藥的黃色申請表

【發行股數】

全球發售項下的發售股份數目:107,065,100股H股(視乎超額配股權行使與否而定)

香港發售股份數目:5,888,600股H股(可予重新分配)

國際發售股份數目:101,176,500股H股(可予重新分配及視乎超額配股權行使與否而定)

【招股看點】

1、行業地位領先:泰格醫藥是中國最大,全球前十的臨床合同研究機構。A股上市8年,累計升幅2622.97%(截至7月27日收市 )。

2、業績穩定增長:2017年、2018年、2019年的總收入分別為16.825億(單位:人民幣,下同)、22.995億、28.033億,複合年增長率為29.1%。s

淨利潤分別為3.942億、6.552億、9.749億,複合年增長率為57.3%

3、外資"買爆"泰格醫藥A股:截至7月16日,泰格醫藥的外資(QFII/RQFII/深股通投資者)持股比例高達26.17%,達到警戒線,說明外資青睞。

資料來源:深圳證券交易所

根據根據滬深交易所規定,外資持股臨界點分別為警戒點26%、暫停買入點28%與強制減持點30%。

4、二級市場追捧CRO概念:港A美的CRO概念股,股價歷史表現優秀。

5、明星機構加持:淡馬錫持股2.57%、高瓴資本持股1%(於全球發售前)今年高瓴資本概念IPO整體表現亮眼。

6CRO行業持續高景氣:中國臨床CRO在CRO行業中佔比最大,2019年達到54.4%,預計於2019年至2024年,有關增速將高於整體CRO市場。

風險提示:

歷史資料僅供參考,不代表投資建議。打新有風險,投資者需要閱讀招股書後做出是否申購的選擇。

點擊可閱讀《泰格醫藥招股書》原文PDF。

 

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account